Details
Stereochemistry | ACHIRAL |
Molecular Formula | C3H5N3O9 |
Molecular Weight | 227.0865 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[O-][N+](=O)OCC(CO[N+]([O-])=O)O[N+]([O-])=O
InChI
InChIKey=SNIOPGDIGTZGOP-UHFFFAOYSA-N
InChI=1S/C3H5N3O9/c7-4(8)13-1-3(15-6(11)12)2-14-5(9)10/h3H,1-2H2
Molecular Formula | C3H5N3O9 |
Molecular Weight | 227.0865 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16103363 |
https://www.ncbi.nlm.nih.gov/pubmed/22040938
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/16103363 |
https://www.ncbi.nlm.nih.gov/pubmed/22040938
Nitroglycerin was first invented in 1847 and has been used as an active ingredient in the manufacture of explosives, mostly dynamite. Nitroglycerin came into medical use in 1878 as as a potent vasodilator (dilation of the vascular system) to treat heart conditions, such as angina pectoris and chronic heart failure. Upon administration, nitroglycerin is converted to nitric oxide (NO) by mitochondrial aldehyde dehydrogenase. NO is a potent activator of guanylyl cyclase (GC) by heme-dependent mechanisms.
CNS Activity
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/22040938
Curator's Comment: Nitroglycerin was first synthesized by the Italian chemist Ascanio Sobrero in 1847, working under Théophile-Jules Pelouze at the University of Turin
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2111348 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NITROSTAT Approved UseAcute relief of angina pectoris secondary to CAD; acute prophylactic management in situations likely to provoke angina attacks; and long-term prophylactic management of angina pectoris. Launch Date9.4703039E11 |
|||
Primary | NITROGLYCERIN Approved UseManagement of patients with acute myocardial infarction (MI). Nitroglycerin is one of the principal initial therapies of MI. Launch Date3.71174408E11 |
|||
Primary | NITROGLYCERIN Approved UseIV nitroglycerin is used to control BP in perioperative hypertension, especially hypertension associated with cardiovascular procedures; to control BP in patients with severe hypertension† or in hypertensive crises for the immediate reduction of BP in patients in whom such reduction is considered an emergency (hypertensive emergencies), especially those associated with coronary complications (e.g., coronary ischemia, acute coronary insufficiency, acute left ventricular failure, postoperative hypertension [especially following coronary bypass surgery]); and to produce controlled hypotension during surgical procedures. Launch Date3.71174408E11 |
|||
Primary | NITROGLYCERIN Approved UseIV nitroglycerin has been used in the management of acutely decompensated (e.g., congestive) heart failure and other low cardiac-output states. Launch Date3.71174408E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.7 pg/mL |
800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered: |
NITROGLYCERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
84 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/ |
13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered: |
GLYCERYL 1,2-DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12.3 pg × min/mL |
800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered: |
NITROGLYCERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
3380 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/ |
13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered: |
GLYCERYL 1,2-DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
40 min |
800 μg single, sublingual dose: 800 μg route of administration: Sublingual experiment type: SINGLE co-administered: |
NITROGLYCERIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
50 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/2111749/ |
13 mg single, oral dose: 13 mg route of administration: Oral experiment type: SINGLE co-administered: |
GLYCERYL 1,2-DINITRATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
1 ug/kg/min multiple, intravenous (starting) Dose: 1 ug/kg/min Route: intravenous Route: multiple Dose: 1 ug/kg/min Sources: |
pregnant, 26 years n = 16 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 16 Sources: |
Disc. AE: Hypotension... AEs leading to discontinuation/dose reduction: Hypotension (4 patients) Sources: |
8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: |
pregnant, 26 years n = 1 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 1 Sources: |
Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea (severe, 1 patient) Sources: Vomiting (severe, 1 patient) Headache (severe, 1 patient) |
35 ug/kg/min single, intravenous Dose: 35 ug/kg/min Route: intravenous Route: single Dose: 35 ug/kg/min Sources: |
unhealthy, 50 years (range: 19 ± 74 years) n = 105 Health Status: unhealthy Age Group: 50 years (range: 19 ± 74 years) Sex: M+F Population Size: 105 Sources: |
Disc. AE: Hemodynamic test abnormal... AEs leading to discontinuation/dose reduction: Hemodynamic test abnormal (8 patients) Sources: |
0.6 mg/h 1 times / day multiple, transdermal Highest studied dose Dose: 0.6 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.6 mg/h, 1 times / day Sources: |
unhealthy, 51.4 ±4.3 years n = 11 Health Status: unhealthy Condition: menopausal hot flashes Age Group: 51.4 ±4.3 years Sex: F Population Size: 11 Sources: |
|
2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: |
unhealthy, 57 - 71 years n = 2 Health Status: unhealthy Age Group: 57 - 71 years Sex: M Population Size: 2 Sources: |
Disc. AE: Pruritic rash, Erythema edematous... AEs leading to discontinuation/dose reduction: Pruritic rash (2 patients) Sources: Erythema edematous (2 patients) Vesicular eruption (2 patients) |
40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy, 80 years n = 1 Health Status: unhealthy Condition: angina pectoris Age Group: 80 years Sex: M Population Size: 1 Sources: |
Other AEs: Methemoglobinemia... Other AEs: Methemoglobinemia (grade 5, 1 patient) Sources: |
0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: |
unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: |
Other AEs: Headache, Lightheadedness... Other AEs: Headache (63%) Sources: Lightheadedness (6%) Hypotension (4%) Syncope (4%) |
1.5 mg 2 times / day multiple, rectal Dose: 1.5 mg, 2 times / day Route: rectal Route: multiple Dose: 1.5 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Disc. AE: Hypotension... AEs leading to discontinuation/dose reduction: Hypotension Sources: |
5 ug/kg 1 times / day single, subcutaneous Dose: 5 ug/kg, 1 times / day Route: subcutaneous Route: single Dose: 5 ug/kg, 1 times / day Sources: |
unhealthy, pediatric n = 57 Health Status: unhealthy Age Group: pediatric Population Size: 57 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Hypotension | 4 patients Disc. AE |
1 ug/kg/min multiple, intravenous (starting) Dose: 1 ug/kg/min Route: intravenous Route: multiple Dose: 1 ug/kg/min Sources: |
pregnant, 26 years n = 16 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 16 Sources: |
Headache | severe, 1 patient Disc. AE |
8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: |
pregnant, 26 years n = 1 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 1 Sources: |
Nausea | severe, 1 patient Disc. AE |
8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: |
pregnant, 26 years n = 1 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 1 Sources: |
Vomiting | severe, 1 patient Disc. AE |
8 ug/kg/min multiple, intravenous Dose: 8 ug/kg/min Route: intravenous Route: multiple Dose: 8 ug/kg/min Sources: |
pregnant, 26 years n = 1 Health Status: pregnant Condition: Preterm labor Age Group: 26 years Sex: F Population Size: 1 Sources: |
Hemodynamic test abnormal | 8 patients Disc. AE |
35 ug/kg/min single, intravenous Dose: 35 ug/kg/min Route: intravenous Route: single Dose: 35 ug/kg/min Sources: |
unhealthy, 50 years (range: 19 ± 74 years) n = 105 Health Status: unhealthy Age Group: 50 years (range: 19 ± 74 years) Sex: M+F Population Size: 105 Sources: |
Erythema edematous | 2 patients Disc. AE |
2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: |
unhealthy, 57 - 71 years n = 2 Health Status: unhealthy Age Group: 57 - 71 years Sex: M Population Size: 2 Sources: |
Pruritic rash | 2 patients Disc. AE |
2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: |
unhealthy, 57 - 71 years n = 2 Health Status: unhealthy Age Group: 57 - 71 years Sex: M Population Size: 2 Sources: |
Vesicular eruption | 2 patients Disc. AE |
2 % 6 times / day multiple, topical Dose: 2 %, 6 times / day Route: topical Route: multiple Dose: 2 %, 6 times / day Sources: |
unhealthy, 57 - 71 years n = 2 Health Status: unhealthy Age Group: 57 - 71 years Sex: M Population Size: 2 Sources: |
Methemoglobinemia | grade 5, 1 patient | 40 mg single, oral Overdose Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: |
unhealthy, 80 years n = 1 Health Status: unhealthy Condition: angina pectoris Age Group: 80 years Sex: M Population Size: 1 Sources: |
Hypotension | 4% | 0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: |
unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: |
Syncope | 4% | 0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: |
unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: |
Lightheadedness | 6% | 0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: |
unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: |
Headache | 63% | 0.2 mg/h 1 times / day multiple, transdermal (starting) Recommended Dose: 0.2 mg/h, 1 times / day Route: transdermal Route: multiple Dose: 0.2 mg/h, 1 times / day Sources: |
unhealthy, adult n = 307 Health Status: unhealthy Age Group: adult Sex: M+F Population Size: 307 Sources: |
Hypotension | Disc. AE | 1.5 mg 2 times / day multiple, rectal Dose: 1.5 mg, 2 times / day Route: rectal Route: multiple Dose: 1.5 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Acute normovolemic hemodilution and nitroglycerin-induced hypotension: comparative effects on tissue oxygenation and allogeneic blood transfusion requirement in total hip arthroplasty. | 1999 Aug |
|
Randomized, double-blind, placebo-controlled trial of diazepam, nitroglycerin, or both for treatment of patients with potential cocaine-associated acute coronary syndromes. | 2000 Aug |
|
Coronary spastic angina induced by anticholinesterase medication for myasthenia gravis--a case report. | 2000 Dec |
|
Glyceryl trinitrate for chronic anal fissure--healing or headache? Results of a multicenter, randomized, placebo-controled, double-blind trial. | 2000 Feb |
|
Effectiveness of modified release isosorbide mononitrate affected by incorrect use. | 2000 Feb 19 |
|
Audit of topical glyceryl trinitrate for treatment of fissure-in-ano. | 2000 Jan |
|
Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability. | 2000 Jan 7 |
|
Glyceryl trinitrate induced headache in migraineurs - relation to attack frequency. | 2000 Jul |
|
Acute myocardial ischemia after administration of ondansetron hydrochloride. | 2000 Mar |
|
Echocardiographic assessment of coronary blood flow velocity during controlled hypotensive anesthesia with nitroglycerin. | 2000 Oct |
|
Nitroglycerin is preferable to diltiazem for prevention of coronary bypass conduit spasm. | 2000 Sep |
|
The use of intravenous nitroglycerin in a case of spasm of the sphincter of Oddi during laparoscopic cholecystectomy. | 2001 Apr |
|
Treatment of anal fissure with glyceryl trinitrate in patients referred for surgical management. | 2001 Apr |
|
Does nitric oxide play a role in the aetiology of pre-eclampsia? | 2001 Apr |
|
Topical diltiazem ointment in the treatment of chronic anal fissure. | 2001 Apr |
|
Effects of nitrovasodilators on the human fetal-placental circulation in vitro. | 2001 Apr |
|
S-Transnitrosylation of albumin in human plasma and blood in vitro and in vivo in the rat. | 2001 Apr 7 |
|
Improved analysis of brachial artery ultrasound using a novel edge-detection software system. | 2001 Aug |
|
Effects of nitric oxide donors on the contractility and prostaglandin synthesis of myometrial strips from pregnant and non-pregnant women. | 2001 Feb |
|
Cardiac natriuretic peptides--hope or hype? | 2001 Feb |
|
Acute myocardial infarction secondary to coronary vasospasm during withdrawal from industrial nitroglycerin exposure--a case report. | 2001 Feb |
|
Reduced venous responsiveness to endothelin-1 but not noradrenaline in hypertensive chronic renal failure. | 2001 Feb |
|
Does renal failure cause an atherosclerotic milieu in patients with end-stage renal disease? | 2001 Feb 15 |
|
Enhanced 99Tc(m)-MIBI SPECT detection of hibernating myocardium following the use of sub-lingual nitroglycerine. | 2001 Jan |
|
Assessment of skin safety of a new glyceryl trinitrate transdermal patch. Animal and human studies. | 2001 Jan |
|
YC-1 enhances the responsiveness of tolerant vascular smooth muscle to glyceryl trinitrate. | 2001 Jan |
|
Acute congestive heart failure associated with a limited form of systemic sclerosis and primary biliary cirrhosis. | 2001 Jan |
|
Migraine with aura after administration of sublingual nitroglycerin tablets. | 2001 Jan |
|
Impaired vasodilator response to organic nitrates in isolated basilar arteries. | 2001 Jan |
|
Effect of isosorbide dinitrate on nitric oxide synthase under hypoxia. | 2001 Jan |
|
Prehospital management of rapid atrial fibrillation: recommendations for treatment protocols. | 2001 Jan |
|
Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes. | 2001 Jan |
|
Effects of C-peptide on forearm blood flow and brachial artery dilatation in patients with type 1 diabetes mellitus. | 2001 Jul |
|
Different mechanisms of isoproterenol-induced and nitroglycerin-induced syncope during head-up tilt in patients with unexplained syncope: important role of epinephrine in nitroglycerin-induced syncope. | 2001 Jul |
|
Gender difference in age-related changes in vascular function. | 2001 Jul |
|
Pseudonormal diastolic filling unmasked with glyceryl trinitrate in patients with type 2 diabetes with poor metabolic control. | 2001 Jul |
|
Reduction of organic nitrates catalysed by xanthine oxidoreductase under anaerobic conditions. | 2001 Jul 2 |
|
The effect of nitric oxide donors and L-arginine on the gastric electrolyte barrier. | 2001 Jun |
|
Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles. | 2001 Jun |
|
Nitric oxide in primary headaches. | 2001 Jun |
|
Ecstasy induced acute myocardial infarction. | 2001 Jun |
|
Calcitonin gene-related peptide levels during nitric oxide-induced headache in patients with chronic tension-type headache. | 2001 Mar |
|
Reciprocal regulation of cGMP-mediated vasorelaxation by soluble and particulate guanylate cyclases. | 2001 Mar |
|
Urban-rural differences in the quality of care for medicare patients with acute myocardial infarction. | 2001 Mar 12 |
|
Endothelium-dependent and independent vasodilation studies at normoglycaemia in type I diabetes mellitus with and without microalbuminuria. | 2001 May |
|
Functional immunohistochemistry of neuropeptides and nitric oxide synthase in the nerve fibers of the supratentorial dura mater in an experimental migraine model. | 2001 May 1 |
|
[Nitrate headache in blasting work]. | 2001 May 15 |
|
Heart preservation with celsior solution improved by the addition of nitroglycerine. | 2001 May 27 |
|
Treatment of chronic anal fissure with topical glyceryl trinitrate: a double-blind, placebo-controlled trial. | 2001 May-Jun |
Patents
Sample Use Guides
Nitroglycerin in 5% Dextrose Injection is intended for intravenous administration using sterile equipment. It should be administered only via an infusion pump that can maintain a constant infusion rate.
For treatment of acute anginal attack, one tablet of Nitrostat should be dissolved under the tongue or in the buccal pouch at the first sign of an acute anginal attack. The dose may be repeated approximately every 5 minutes, until relief is obtained. If the pain persists after a total of 3 tablets in a 15-minute period, or the pain is different than is typically experienced, prompt medical attention is recommended. Nitrostat may be used prophylactically 5 to 10 minutes prior to engaging in activities which might precipitate an acute attack.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16103363
Vasoactivity of nitroglycerin was measured using an ex vivo assay. Mice thoracic aortae were removed, cleaned, and cut into 3-mm rings. Rings were mounted on strain gauge transducers under 1 g of resting tension, and maintained at 37°C in Krebs solution, bubbled continuously with 20% O2/5% CO2/75% N2. Rings were allowed to equilibrate for 1 h before active tension was induced with prostaglandin F2α. Application of Nitroglycerine relieve the F2α-induced strain with IC50 of 10-7 M for wt mice, and 10-5 for mtALDH-/- mice.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:45:49 UTC 2023
by
admin
on
Wed Jul 05 22:45:49 UTC 2023
|
Record UNII |
G59M7S0WS3
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC05AE01
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
||
|
WHO-VATC |
QC01DA02
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
||
|
CFR |
21 CFR 250.102
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
||
|
NDF-RT |
N0000007647
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
||
|
NDF-RT |
N0000007647
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/15/1435
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
||
|
NCI_THESAURUS |
C29707
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
||
|
WHO-ATC |
C01DA52
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
||
|
WHO-ATC |
C05AE01
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
||
|
LIVERTOX |
691
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
||
|
NDF-RT |
N0000007647
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
||
|
NDF-RT |
N0000009909
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
12.1
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
||
|
WHO-VATC |
QC01DA52
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
||
|
NDF-RT |
N0000007647
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
||
|
NDF-RT |
N0000175415
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
||
|
WHO-ATC |
C01DA20
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
||
|
WHO-ATC |
C01DA02
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Nitroglycerin (medication)
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
200-240-8
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
G59M7S0WS3
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
G59M7S0WS3
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
4510
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
1952
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
NITROGLYCERIN
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
30
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
SUB11999MIG
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
DTXSID1021407
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
100000087614
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
C29294
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
7053
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
CHEMBL730
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
M7964
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | Merck Index | ||
|
DB00727
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
1466506
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
Nitroglycerin
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
SUB13997MIG
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
55-63-0
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
4917
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | RxNorm | ||
|
SUB90670
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
34104
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
9010-02-0
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
SUPERSEDED | |||
|
28787
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
D005996
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
PRIMARY | |||
|
SUB96541
Created by
admin on Wed Jul 05 22:45:49 UTC 2023 , Edited by admin on Wed Jul 05 22:45:49 UTC 2023
|
ALTERNATIVE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||